Rich received his Ph.D. in Biochemistry from the University of Massachusetts at Amherst in 1986, followed by post-doctoral research in cancer genetics at the Worcester Foundation for Experimental Biology in Shrewsbury MA. In 1989 he joined Genzyme Corporation, where he was responsible for a number of discovery projects in the molecular biology department. In 1990, his group at Genzyme was the first to express the cystic fibrosis transmembrane conductance regulator (CFTR) and to determine the molecular defect caused by the most common mutation of CFTR. Richard received the Genzyme President’s award for this work in 1991. This research on the molecular basis of cystic fibrosis led to the development of Genzyme’s CF gene therapy program, for which Richard was Project Team Leader until 1993. From 1993 to 1995 he was Director of Molecular Biology at Canji, Inc. in San Diego, where he conducted research on development of gene therapies for cancer. Dr. Gregory returned to Genzyme in 1995 to head the gene therapy program as Vice President for Gene Therapy. Research efforts under Dr. Gregory’s direction during this period included programs in cancer immunotherapy, gene therapies for genetic diseases and cardiovascular gene therapy. In 2003, Richard was appointed Head of Research for Genzyme Corporation and currently is responsible for oversight of pre-clinical research conducted at Genzyme. He is the co-author of over 60 peer-reviewed publications and 17 issued U.S. patents in the area of biotechnology.